HSK46256 / Haisco - LARVOL DELTA

HSK46256, a highly selective and brain penetrable PARP1 inhibitor for the treatment of HRD cancers (AACR 2025) - "The CNS penetration of HSK46256 in rodent showed an unbound partition coefficient (Kpuu) of 0.32, indicating good CNS penetration compared to Kpuu of 0.25 of AZD9574. HSK46256 may offer a more efficacious and less toxic cancer treatment compared with currently approved PARPi especially when used in combination with other anti-cancer agents. Furthermore, owing to its CNS penetration capability HSK46256 may provide a new treatment option for patients with CNS malignancies or patients with brain metastases, where HRR suppression or HRD exists or for cancers with high rates of brain metastases."

Late-breaking abstract • Brain Cancer • CNS Tumor • Oncology • Solid Tumor • BRCA • HRD • PARP2